Demographics
| | | |
Age (years), mean (SD) | 46.5 (11.3) | | 47.1 (12.8) |
Sex, male (%) | 51 (51) | | 71 (71) |
Race, white (%) | 94 (94) | | 95 (95) |
| | | |
Baseline disease characteristics* | | | |
PsA duration (years) | 7.5 | | 8.4 |
Psoriasis duration (years) | 16.8 | | 16.2 |
Patients with at least 3% BSA psoriasis involvement (%) | 87/98 (89) | | 83/100 (83) |
PASI score (0–72) | 10.2 | | 11.4 |
Number of swollen joints (0–66) | 14.4 | | 13.9 |
Number of tender joints (0–68) | 25.1 | | 24.6 |
Duration of morning stiffness (0–1440 min) | 183.4 | | 216.0 |
Patient’s assessment of pain (VAS; 0–10 cm) | 5.9 | | 5.6 |
| | | |
Physical function/quality of life* | | | |
HAQ score (0–3) | 1.1 | | 1.1 |
PCS score of SF-36 | 31.0 | | 33.0 |
MCS score of SF-36 | 47.0 | | 45.5 |